CDEK
← All drugs Report issue

autologous natural killer cells

Cell therapyexperimental

Clinical trial activity

74 trials · 68 clinical orgs · 0 marketing orgs

Phase 1
59
Phase 2
39
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2006 (NCT00402558)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • alloreactive nk cells
  • autologous natural killer cells
  • expanded natural killer cells

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07144384Early Phase 1 (Phase 1)Oct 16, 2025Ohio State University
NCT06783478Phase 2Apr 1, 2025Federal University of Health Science of Porto Alegre
NCT06821685Phase 1Feb 13, 2025Nanjing University, University of Science and Technology of China
NCT06758726N/ADec 31, 2024China Academy of Chinese Medical Sciences
NCT06687681Phase 2Nov 25, 2024Kian Immune Cell Company
NCT06318871Early Phase 1 (Phase 1)Aug 28, 2024Harvard University
NCT06342986Phase 1Jul 11, 2024National Cancer Institute (NCI), University of Minnesota
NCT06441084Phase 1Jun 30, 2024Capital Medical University, Nuwacell Biotechnologies Co., Ltd.
NCT06367673Phase 1Apr 30, 2024Zhejiang University
NCT05834244Phase 1Oct 26, 2023University of Texas at Houston
NCT05909098Phase 1/Phase 2 (Phase 2)Jul 1, 2023Xiang Yang NO.1 People's Hospital
NCT07202611Phase 2Dec 2, 2022National Taiwan University
NCT05588453Phase 1/Phase 2 (Phase 2)Nov 1, 2022Ohio State University
NCT05319249Phase 1/Phase 2 (Phase 2)Sep 30, 2022German Cancer Research Center
NCT06044506Phase 1Aug 29, 2022University of Indonesia
NCT05395052Phase 1May 31, 2022Fate Therapeutics
NCT05371730Early Phase 1 (Phase 1)May 30, 2022Nuwacell Biotechnologies Co., Ltd., University of Science and Technology of China
NCT05385705Phase 1May 11, 2022Autonomous University of Madrid, Banc de Sang i Teixits, Clinica Universidad de Navarra, Universidad Autonoma de Barcelona
NCT04848064Phase 1Nov 1, 2021Ohio State University
NCT05272293Phase 1/Phase 2 (Phase 2)Nov 1, 2021Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Showing 20 of 74 trials
Page 1 / 4

Organizations

Research & Development (68)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Jinan UniversityAcademic/Hospital141412016
Shenzhen Hank Bioengineering InstituteGovernment14012016
University of Texas at HoustonAcademic/Hospital5522006
Ohio State UniversityAcademic/Hospital4422020
National Cancer Institute (NCI)Government3022009
People's Liberation Army of ChinaGovernment3222016
University of Science and Technology of ChinaAcademic/Hospital3012020
Capital Medical UniversityAcademic/Hospital2122018
Federal University of Health Science of Porto AlegreAcademic/Hospital2212016
Harvard UniversityAcademic/Hospital2212008
Jilin UniversityAcademic/Hospital2212018
Karolinska InstituteAcademic/Hospital2222014
Nuwacell Biotechnologies Co., Ltd.For profit2212022
Peking UniversityAcademic/Hospital2112019
Shenzhen UniversityAcademic/Hospital2222019
State of TexasGovernment2012013
University of BolognaAcademic/Hospital2212018
University of MinnesotaAcademic/Hospital2222017
Allife Medical Science and Technology Co., Ltd.For profit1112019
Altor BioscienceFor profit1012017
68 organizations
Page 1 / 4